Association of the Lung Immune Prognostic Index (LIPI) with Outcomes for Immune Checkpoint Inhibitors in Diffuse SCLC Patients [P3.12-11]
(2018) IASLC 19th World Conference on Lung Cancer — Location: (Canada) Toronto (23.September.2018)
Files
2018_Mezquita_J_Thorac_Oncol_P312-11.pdf
Open Access - Adobe PDF
- 372.51 KB
Details
- Authors
- Abstract
- BACKGROUND : Pretreatment LIPI (Lung Immune Prognostic Index), based on derived NLR (neutrophils/[leucocytes-neutrophils] ratio) and lactate dehydrogenase (LDH) has been associated with outcomes for immune checkpoint inhibitors (ICI) in advanced NSCLC patients. We tested whether LIPI has the same role in diffuse small cell lung cancer (SCLC) patients. [...]
- Affiliations
Citations
Mezquita, L., Ponce Aix, S., Auclin, E., Navarro, A., Planchard, D., Sullivan, I., Zalcman, G., Mazieres, J., Hendriks, L., Caramella, C., Majem, M., Lavaud, P., Aboubakar Nana, F., Felip, E., Paz-Ares, L., & Besse, B. (2018). Association of the Lung Immune Prognostic Index (LIPI) with Outcomes for Immune Checkpoint Inhibitors in Diffuse SCLC Patients [P3.12-11]. Journal of Thoracic Oncology, 13(10), S973-S974. https://doi.org/10.1016/j.jtho.2018.08.1834 (Original work published 2018)